An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

Non ancora tradotto Non ancora tradotto
Autori
Categoria Primary study
Registry of Trialsclinicaltrials.gov
Year 2015

Questo articolo fa parte di 1 Systematic review Systematic reviews (1 reference)

This article is part of the following publication threads:
Loading references information
The purpose of this study is to evaluate the efficacy and safety of vedolizumab intravenous (IV) treatment compared to adalimumab subcutaneous (SC) treatment over a 52-week treatment period.
Epistemonikos ID: 401dd724b7c6f5d65271f07f774c9c387a184bb5
First added on: Dec 18, 2021